The Safety and Efficacy of SYD-101 in Children With Myopia
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of
adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of
developing other eye conditions such as glucoma, cataracts and retinal detachment, which may
lead to blindness. Early treatment of myopia in children could help slow the condition and
minimize the risk of complications later in life. This study investigates the use of SYD-101,
an eye solution, in slowing-down the progression of myopia in children.